Almac Group Announces New COO and Appoints New Almac Pharma Services MD
October 4, 2022
The Almac Group, the global contract pharmaceutical development and manufacturing organisation, has announced the appointment of Graeme McBurney to the Board of Directors in the role of Chief Operating Officer effective 1st October 2022.
Graeme has over 30 years’ experience in the pharmaceutical industry. He joined the Almac Group in 1990 and has held a number of operational and management positions, most recently as Managing Director and President of Almac Pharma Services since 2003.
In his new role, Graeme will be responsible for implementing operations aligned with long term business goals and the Group’s strategies. He will oversee operations of the Group and work with Almac Executives to secure the functionality of the business to drive continued growth.
Almac has also announced today that John McQuaid will succeed Graeme as Managing Director and President of Almac Pharma Services, which provides a range of pharmaceutical development, manufacture and commercial services. John will now be responsible for overall strategic, operational and financial leadership of the Almac Pharma Services business.
John has been with Almac since 1994 and has held a number of management roles including project management, production and quality. He was appointed Vice President of Technical Operations in 2011 where he was responsible for overseeing the strategic growth and development of the Pharmaceutical Development service offering within Almac Pharma Services.
Alan Armstrong, CEO Almac Group, said: “We are delighted to welcome Graeme to the Board at this exciting time as we progress our global growth strategy. His wealth of experience and expertise will be instrumental in supporting our vision and congratulations to John on his new role as he leads Almac Pharma Services.”
Graeme commented: “I am honoured to join the Almac Group Board of Directors and look forward to the next phase of Almac’s evolution as we remain focused on our client relationships and the continued strategic growth of the Group. I also congratulate John on his promotion to MD of Almac Pharma Services. Having worked alongside John for many years, I am confident his technical knowledge and expertise coupled with strategic management experience is the perfect blend to lead and evolve the business.”
This announcement comes just months after the Group announced a £200m global expansion having recorded a £58m (8.6%) rise in turnover from £677m in 2020 to £735m in 2021 and a 5.8% increase in the Group’s average employee figures from 5,466 to 5,783 from October 2020 to September 2021.
About Almac Group
A unique culture delivering exceptional solutions
The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.
Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation which has grown organically over the past five decades now employing over 6,600 highly skilled personnel across 18 facilities including Europe, the US and Asia.
To keep up to date with latest news, follow us on Twitter and LinkedIn or visit almacgroup.com.
About Almac Pharma Services
Tailormade pharmaceutical development and commercial solutions
With over 50 years’ experience, Almac Pharma Services is a world leading outsourcing partner to the global pharmaceutical and biotechnology industry.
With facilities located in Europe and the US, we provide tailored, quality-led and timely solutions from early and late phase pharmaceutical development, commercial drug product manufacture, commercial packaging through to global storage & distribution.